Researchers are beginning to wonder whether blockbuster drugs such as Wegovy, Ozempic and Zepbound could play a role in ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 ...

WeightWatchers filed for bankruptcy on Tuesday as Americans shunned its offerings in favor of Novo and Lilly drugs and copies from pharmacies that can cut a person's weight by as much as 20%.

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and diabetes drugs Zepbound and Mounjaro off a list of medicines in short supply, ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down FRANKFURT, Germany -- Pharmaceutical company Novo Nordisk A/S, maker of blockbuster ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Novo Nordisk, the maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by "mutual agreement" with the company's board of directors, citing "recent market challenges ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

“Two drugs together can produce better weight loss,” said Aronne, who led the study and presented the findings Sunday at the European Congress on Obesity in Spain. While tirzepatide won out in ...